title: [Gastrinomas in multiple endocrine neoplasia type-1. A 127-case cohort study from the endocrine tumor group (ETG)].
abstract: On July 2000, 127 gastrinomas (31.1%) were studied by the Endocrine Tumour Group (GTE) using a 408-patient cohort of Multiple Endocrine Neoplasia Type 1 patients. The aim of this study was to assess clinical, biological, surgical data as well as their trends over three periods (<1980-1980/1989->1990). A Zollinger-Ellison syndrome (SZE) was present in 96% of the cases. Mean age at the onset of the disease was 39.4 years. There were 55.9% of men. Synchronous liver metastasis was present in 7.1%. Taken independently, the positivity of the four main diagnosis tests decreased over the time. The diagnosis of oesophagitis increased (4.5-29.7%), as well as the size of the resected tumours (9.9-16.8 mm). There was an increase in the familial background diagnosis (73.1-80%), an increasing use of Octreoscan scintigraphy and transduodenal ultrasound with positive detection of metastasis and tumours in 81.3% and 92.3%, respectively after 1991. Patients were operated on less frequently (96-52.5%), less frequently from the pancreas (87.5-37.5%), and from the gastro-intestinal tract (70.8-30%). The relative percentage of major pancreatic resections increased (with at least removal of the duodenum and the pancreatic head) (10-26.7%). The operative mortality disappeared. Six out of the seven patients (85.7%) who benefited from major pancreatic resections normalized their gastrine level postoperatively versus 15% in less radical techniques. Overall 5 years survival was 90 +/- 4.4%. Survival increased after 1985 (85 +/- 4.8% versus 95 +/- 3.6, P = 0.1).
  
  
  CONCLUSIONS
  SZE in NEM1 were diagnosed at an earlier stage and were less frequently operated on. Nevertheless, the incidence of synchronous metastasis did not change significantly. Patients were mainly operated on for gastric emergencies and pancreatic tumours in order to prevent metastasis without mortality after 1991.
authors.affiliation: Service de chirurgie viscérale et endocrinienne, CHU de Dijon, 3, rue du Faubourg-Raines, BP 1519, 21033 Dijon cedex, France. pierre.goudet@chu-dijon.fr
authors.forename: P
authors.initials: P
authors.lastname: Goudet
authors.forename: F
authors.initials: F
authors.lastname: Peschaud
authors.forename: M
authors.initials: M
authors.lastname: Mignon
authors.forename: P
authors.initials: P
authors.lastname: Nicoli-Sire
authors.forename: G
authors.initials: G
authors.lastname: Cadiot
authors.forename: P
authors.initials: P
authors.lastname: Ruszniewski
authors.forename: A
authors.initials: A
authors.lastname: Calender
authors.forename: A
authors.initials: A
authors.lastname: Murat
authors.forename: E
authors.initials: E
authors.lastname: Sarfati
authors.forename: J L
authors.initials: JL
authors.lastname: Peix
authors.forename: J L
authors.initials: JL
authors.lastname: Kraimps
authors.forename: J F
authors.initials: JF
authors.lastname: Henry
authors.forename: P
authors.initials: P
authors.lastname: Cougard
authors.forename: C
authors.initials: C
authors.lastname: Proye
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D015408:Gastrinoma / Q000097:blood / Q000175:diagnosis / Q000601:surgery*; D005755:Gastrins / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000097:blood / Q000175:diagnosis / Q000601:surgery*; D010190:Pancreatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000601:surgery*; D011379:Prognosis
chemical_list: D005755:Gastrins